AFT Pharmaceuticals
(ASX:AFP) has started the commercialization program for its patented Maxigesic intravenous formulation (IV).
The company has signed a licensing agreement with South Korean company, Kyongbo Pharmaceutical
The Maxigesic IV infusion has been developed as a line extension to Maxigesic tablets for use post-operativly in hospitals.
A major phase 3 study clinical trial conducted in Texas and Maryland found that Maxigesic IV provided significantly better pain relief than either paracetamol or ibuprofen.
Shares in AFT Pharmaceuticals
(ASX:AFP) are Flat at $2.05.
